The management of ocular herpesvirus infections.
The many treatment methods in current use for every known complaint only seem to aggravate the difficulty of treating ocular herpes simplex virus (HSV) infections, which are generally self-limited in the immunocompetent host. The cornea is already a somewhat immune-deficient tissue since its lack of blood vessels separates it partially from the host, and treatment with glucocorticoids, which are immunosuppressive, increases the risk of damaging complications such as scarring, prolonged morbidity, bacterial or fungal superinfection, and the occasional corenal perforation. Accepted methods of treatment of specific lesions, are discussed, as are some methods that are not yet accepted, but which seem promising. Herpes zoster may result in scarring and significant loss of vision even without the use of glucocorticoids, the disease often manifesting itself in the already compromised host. The major complication is postherpetic neuralgia. None of the available treatment methods has been fully satisfactory, and every effort should be made to prevent eye lesions in patients with early infection of the ophthalmic branch of the trigeminal nerve. Stimulation of cellular immunity by various means appears to offer some new promise for control of the disease. Management of varicella, cytomegalovirus, and infectious mononucleosis are also discussed.
D000818:Animals; D001089:Arabinose / Q000031:analogs & derivatives; D001241:Aspirin / Q000627:therapeutic use; D003231:Conjunctivitis / Q000188:drug therapy; D003261:Contact Lenses; D003452:Cryosurgery; D003561:Cytarabine / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006561:Herpes Simplex / Q000188:drug therapy; D006563:Herpes Zoster Ophthalmicus / Q000628:therapy*; D006801:Humans; D007042:Hypoxanthines / Q000627:therapeutic use; D007065:Idoxuridine / Q000627:therapeutic use; D007369:Interferon Inducers / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D007635:Keratitis, Dendritic / Q000517:prevention & control / Q000601:surgery / Q000628:therapy*; D009437:Neuralgia / Q000188:drug therapy; D009705:Nucleosides / Q000627:therapeutic use; D011070:Poly I-C / Q000627:therapeutic use; D011817:Rabbits; D012008:Recurrence; D014740:Vidarabine / Q000627:therapeutic use
D005938:Glucocorticoids; D007042:Hypoxanthines; D007369:Interferon Inducers; D009705:Nucleosides; D003561:Cytarabine; D007372:Interferons; D001089:Arabinose; D014740:Vidarabine; D007065:Idoxuridine; D011070:Poly I-C; D001241:Aspirin